BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26871713)

  • 1. The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
    Ham JS; Kim SJ; Choi JY; Hyun SH; Choi SK; Kim HS; Lim SH; Lee JY; Jung SH; Ko YH; Kim WS
    Blood Cancer J; 2016 Feb; 6(2):e395. PubMed ID: 26871713
    [No Abstract]   [Full Text] [Related]  

  • 2. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
    Toya T; Nannya Y; Hangaishi A; Shiseki M; Shimoyama T; Sakamaki H; Motoji T; Usuki K; Nakamura F; Kurokawa M
    Leuk Lymphoma; 2016; 57(4):961-4. PubMed ID: 26366623
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnosis and treatment of peripheral T-cell lymphoma].
    Suzumiya J; Moriyama I; Kawakami K
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():519-24. PubMed ID: 23134009
    [No Abstract]   [Full Text] [Related]  

  • 5. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
    Mehta-Shah N; Ito K; Bantilan K; Moskowitz AJ; Sauter C; Horwitz SM; Schöder H
    Blood Adv; 2019 Jan; 3(2):187-197. PubMed ID: 30670535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
    Quesada AE; Rios A; Brown RE; Nguyen ND
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S87-9. PubMed ID: 25486962
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
    Oki Y; Younes A; Copeland A; Hagemeister F; Fayad LE; McLaughlin P; Shah J; Fowler N; Romaguera J; Kwak LW; Pro B
    Br J Haematol; 2013 Jul; 162(1):138-41. PubMed ID: 23590726
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
    Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
    Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term survival after nasal NK/T cell lymphoma].
    Rajnics P; Krenács L; Kenéz A; Járay Z; Bagdi E; Demeter J
    Orv Hetil; 2008 Apr; 149(17):801-5. PubMed ID: 18426762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thoracic subcutaneous infiltration: an unusual presentation of subcutaneous panniculitis-like T-cell lymphoma.
    Ballanger F; Barbarot S; Le Gouill S; Gaillard F; Cassagnau E; Lodé L; Dréno B; Stalder JF
    Acta Derm Venereol; 2009; 89(4):427-9. PubMed ID: 19688166
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.
    Jung SH; Ahn JS; Kim YK; Kweon SS; Min JJ; Bom HS; Kim HJ; Chae YS; Moon JH; Sohn SK; Lee SW; Byun BH; Do YR; Lee JJ; Yang DH
    BMC Cancer; 2015 Mar; 15():198. PubMed ID: 25879747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone.
    Suzuki K; Terui Y; Nakano K; Nara E; Nasu K; Ueda K; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Takahashi S; Hatake K
    Leuk Lymphoma; 2012 May; 53(5):849-54. PubMed ID: 22035416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first case report of composite bone marrow involvement by simultaneously developed peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma.
    Kim HK; Park CJ; Jang S; Cho YU; Park SH; Choi J; Park CS; Huh J; Chung YH; Lee JH
    Ann Lab Med; 2015 Jan; 35(1):152-4. PubMed ID: 25553299
    [No Abstract]   [Full Text] [Related]  

  • 15. Loss of CD3 and TCRγδ expression in a relapsed hepatosplenic T-cell lymphoma.
    Hodkoff A; Bentley P; Xu X
    Leuk Lymphoma; 2018 Feb; 59(2):479-481. PubMed ID: 28573906
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
    Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma.
    Park S; Moon SH; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Ahn HK; Lee JY; Kim SJ; Choi JY; Kim WS
    Am J Hematol; 2012 Sep; 87(9):937-40. PubMed ID: 22730093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
    Jelinek T; Zuchnicka J
    Blood; 2020 May; 135(20):1816. PubMed ID: 32407530
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP.
    Wilcox RA
    Lancet Haematol; 2018 May; 5(5):e182-e183. PubMed ID: 29703333
    [No Abstract]   [Full Text] [Related]  

  • 20. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.